Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Research reports are not currently available for HQ1.SG.

On Thursday, Stifel, a financial services company, announced the initiation of coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target set at $49.00. The firm's positive ...

With our newsletters and social media channels.

Relay Therapeutics Inc ( (RLAY)) has released its Q3 earnings. Here is a breakdown of the information Relay Therapeutics Inc presented to its investors. Relay Therapeutics Inc., a clinical-stage ...

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), retaining the price target of $86.00. Silvan Tuerkcan has given his Buy ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...